Skip to main content
. Author manuscript; available in PMC: 2018 Aug 9.
Published in final edited form as: J Am Chem Soc. 2017 Jul 28;139(31):10597–10600. doi: 10.1021/jacs.7b04726

Figure 3.

Figure 3

TarG is the target of 2. (A) Assay to detect Lipid II abundance after antibiotic treatment, with results for control antibiotics and 2 shown. Extracted Lipid II is labeled with biotin-d-Lys using S. aureus PBP4 to enable detection with HRP-streptavidin. (B) Mutants resistant to 2 (lanes 1–3) were sorted into two groups by plating on amsacrine. Susceptible mutants 1 and 2 had mutations in tarA while amsacrine-resistant mutant 3 had a mutation in tarG (see Table S3, S4 for full list and comparison to other TarG inhibitors). (C) Substitutions in TarG that conferred high level resistance to 2. (D) Disk diffusion assay shows that strain KS002, in which B. subtilis TagGH was replaced with S. aureus TarGH, is sensitive to 2.